LC-MS/MS based determination of basal- and ACTH-stimulated plasma concentrations of 11 steroid hormones: implications for detecting heterozygote CYP21A2 mutation carriers

Eur J Endocrinol. 2015 Oct;173(4):517-24. doi: 10.1530/EJE-14-1084.

Abstract

Objective: Heterozygosity in 21-hydroxylase deficiency (21OHD) has been associated with hyperandrogenemic symptoms in children and adults. Moreover, the carrier status is mandatory for genetic counseling. We aimed at defining a hormonal parameter for carrier detection by mass spectrometry.

Design: Eleven basal and ACTH-stimulated steroid hormones of heterozygous carriers of CYP21A2 mutations and control individuals were compared.

Method: Hormones were determined in plasma samples by liquid chromatography tandem mass spectrometry (LC-MS/MS) in 58 carriers (35 males, 23 females, age range 6-78 years) and 44 random controls (25 males, 19 females, age range 8-58 years).

Results: Heterozygotes could be identified best applying the 17-hydroxyprogesterone+21-deoxycortisol/cortisol×1000 ((17OHP+21S)/F×1000) equation 30 min after ACTH injection. An optimal cut-off value of 8.4 provided 89% sensitivity and specificity. Considering this data and a published frequency of heterozygotes of 1/50 to 1/61, the positive predictive value (PPV) of this cut-off is 12%. Of note, the negative predictive value (NPV) excluding heterozygosity in a given patient is 99.8%.

Conclusion: Considering only marginal biochemical effects anticipated from heterozygosity, the stimulated ((17OHP+21S)/F×1000) identifies and excludes heterozygotes remarkably well. Nevertheless, LC-MS/MS cannot replace genetic testing, since sensitivity and specificity did not reach 100%. However, due to the considerably high NPV of the optimal cut-off and to a specificity of even 100% applying a cut-off higher than 14.7, hormonal assessment of heterozygosity can be of significant aid in conditions with limited access to genetic testing, as in some health care systems. The ((17OHP+21S)/F×1000) equation can guide diagnostic considerations in the differential diagnosis of hyperandrogenism.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 17-alpha-Hydroxyprogesterone / blood
  • Adolescent
  • Adrenal Hyperplasia, Congenital / blood
  • Adrenal Hyperplasia, Congenital / diagnosis*
  • Adrenal Hyperplasia, Congenital / genetics
  • Adrenocorticotropic Hormone*
  • Adult
  • Aged
  • Androstenedione / blood
  • Case-Control Studies
  • Child
  • Chromatography, Liquid
  • Corticosterone / blood
  • Cortisone / blood
  • Cortodoxone / blood
  • Desoxycorticosterone / blood
  • Dihydrotestosterone / blood
  • Female
  • Genetic Carrier Screening / methods*
  • Hormones*
  • Humans
  • Hydrocortisone / blood
  • Male
  • Middle Aged
  • Progesterone / blood
  • Steroid 21-Hydroxylase / genetics*
  • Tandem Mass Spectrometry
  • Testosterone / blood
  • Young Adult

Substances

  • Hormones
  • Dihydrotestosterone
  • Testosterone
  • Androstenedione
  • Desoxycorticosterone
  • Progesterone
  • 21-deoxycortisol
  • 17-alpha-Hydroxyprogesterone
  • Adrenocorticotropic Hormone
  • CYP21A2 protein, human
  • Steroid 21-Hydroxylase
  • Cortisone
  • Corticosterone
  • Cortodoxone
  • Hydrocortisone

Supplementary concepts

  • Congenital adrenal hyperplasia due to 21 hydroxylase deficiency